(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.

The three most active and biggest winners today are Canadian National Railway Company, Abbott Laboratories, and Amicus Therapeutics.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 Canadian National Railway Company (CNI) 129.00 3.79% 2021-10-20 07:14:39
2 Abbott Laboratories (ABT) 122.70 2.82% 2021-10-20 07:13:40
3 Amicus Therapeutics (FOLD) 11.14 2.67% 2021-10-20 07:08:38
4 Biogen (BIIB) 273.95 2.17% 2021-10-20 07:07:34
5 Regeneron Pharmaceuticals (REGN) 563.63 2.09% 2021-10-20 07:10:23
6 Pinduoduo (PDD) 99.50 2.03% 2021-10-20 07:12:43
7 United Airlines (UAL) 47.10 1.9% 2021-10-20 07:13:18
8 Citizens Financial Group (CFG) 49.95 1.73% 2021-10-20 07:14:28
9 Genmab (GMAB) 46.02 1.59% 2021-10-20 07:12:12
10 ResMed (RMD) 263.80 1.4% 2021-10-20 07:16:59

The three most active and biggest losers today are Novavax, Pool Corporation, and Rio Tinto.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 Novavax (NVAX) 122.30 -23.82% 2021-10-20 07:09:59
2 Pool Corporation (POOL) 440.00 -5.28% 2021-10-20 04:10:34
3 Rio Tinto (RIO) 68.13 -3.89% 2021-10-20 07:16:58
4 Magna International (MGA) 79.90 -3.69% 2021-10-20 07:16:21
5 Interactive Brokers Group (IBKR) 71.04 -3.65% 2021-10-20 07:09:04
6 10x Genomics (TXG) 155.00 -3.57% 2021-10-20 04:13:37
7 Credit Suisse Group (CS) 10.34 -2.45% 2021-10-20 07:14:44
8 Catalyst Pharmaceuticals (CPRX) 5.89 -2.24% 2021-10-20 07:07:53
9 Lennar Corporation (LEN) 97.70 -2.16% 2021-10-20 07:16:08
10 Deutsche Bank (DB) 13.08 -2.1% 2021-10-20 07:14:50

Most Active Premarket Winners today

1. Canadian National Railway Company (CNI) – Premarket: 3.79%

NYSE Composite ended the session with Canadian National Railway Company jumping 0.62% to $124.29 on Wednesday, after four sequential sessions in a row of gains. NYSE Composite jumped 0.75% to $16,988.16, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Canadian National Railway Company is 911704, 58.64% below its average volume of 2204640.

Canadian National Railway Company’s last close was $123.53, 3.8% under its 52-week high of $128.41.

The company’s growth estimates for the present quarter and the next is 15% and 9.6%, respectively.

Canadian National Railway Company’s Revenue

Year-on-year quarterly revenue growth grew by 12.1%, now sitting on 14.2B for the twelve trailing months.

Volatility

Canadian National Railway Company’s last week, last month’s, and last quarter’s current volatility was a positive 1.32%, a negative 0.08%, and a positive 1.33%, respectively.

Canadian National Railway Company’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.32% (last week), 1.36% (last month), and 1.33% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Canadian National Railway Company’s stock is considered to be oversold (<=20).

Canadian National Railway Company’s Stock Yearly Top and Bottom Value

Canadian National Railway Company’s stock is valued at $124.29 at 08:34 EST, below its 52-week high of $128.41 and way above its 52-week low of $98.69.

Canadian National Railway Company’s Moving Average

Canadian National Railway Company’s worth is higher than its 50-day moving average of $116.87 and way above its 200-day moving average of $110.98.

More news about Canadian National Railway Company.

2. Abbott Laboratories (ABT) – Premarket: 2.82%

NYSE Composite ended the session with Abbott Laboratories jumping 2.16% to $119.34 on Wednesday, after two consecutive sessions in a row of losses. NYSE Composite jumped 0.75% to $16,988.16, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Abbott Laboratories is 5690610, 22.91% above its average volume of 4629810.

Abbott Laboratories’s last close was $116.82, 9.93% under its 52-week high of $129.70.

News about Abbott Laboratories today

  • Abbott laboratories stock surges after big profit and sales beats, and upbeat full-year outlook. According to today’s article on MarketWatch, "Shares of Abbott Laboratories rallied 2.8% in premarket trading Wednesday, after the health care company reported third-quarter profit and sales that rose well above expectations, with the strongest growth seen in its diagnostics business, and provided an upbeat full-year outlook. "

Abbott Laboratories’s Sales

Abbott Laboratories’s sales growth is 6.7% for the present quarter and a decline by 9.3% for the next. The company’s growth estimates for the present quarter and the next is a negative 5.1% and a negative 30.3%, respectively.

Abbott Laboratories’s Revenue

Year-on-year quarterly revenue growth grew by 35.3%, now sitting on 37.34B for the twelve trailing months.

Volatility

Abbott Laboratories’s last week, last month’s, and last quarter’s current volatility was a negative 0.05%, a negative 0.72%, and a positive 0.85%, respectively.

Abbott Laboratories’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.38% (last week), 1.20% (last month), and 0.85% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Abbott Laboratories’s stock is considered to be overbought (>=80).

Abbott Laboratories’s Stock Yearly Top and Bottom Value

Abbott Laboratories’s stock is valued at $119.34 at 08:34 EST, below its 52-week high of $129.70 and way higher than its 52-week low of $103.13.

Abbott Laboratories’s Moving Average

Abbott Laboratories’s value is below its 50-day moving average of $123.48 and below its 200-day moving average of $119.59.

More news about Abbott Laboratories.

3. Amicus Therapeutics (FOLD) – Premarket: 2.67%

NASDAQ Composite ended the session with Amicus Therapeutics rising 1.4% to $10.85 on Wednesday, after two successive sessions in a row of losses. NASDAQ Composite rose 0.71% to $15,129.09, after five successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Amicus Therapeutics is 955679, 60.61% below its average volume of 2426410.

Amicus Therapeutics’s last close was $10.70, 57.86% under its 52-week high of $25.39.

The company’s growth estimates for the present quarter and the next is 28% and 33.3%, respectively.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 281.82M for the twelve trailing months.

Volatility

Amicus Therapeutics’s last week, last month’s, and last quarter’s current volatility was a negative 2.21%, a negative 0.66%, and a positive 2.87%, respectively.

Amicus Therapeutics’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.62% (last week), 4.44% (last month), and 2.87% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Amicus Therapeutics’s stock is considered to be overbought (>=80).

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $10.85 at 08:34 EST, way below its 52-week high of $25.39 and way higher than its 52-week low of $8.60.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s worth is under its 50-day moving average of $11.01 and above its 200-day moving average of $10.08.

More news about Amicus Therapeutics.

4. Biogen (BIIB) – Premarket: 2.17%

NASDAQ Composite ended the session with Biogen falling 0.59% to $268.13 on Wednesday, after two consecutive sessions in a row of losses. NASDAQ Composite rose 0.71% to $15,129.09, after five consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Volume

Today’s last reported volume for Biogen is 1766650, 83.16% above its average volume of 964535.

Biogen’s last close was $269.73, 42.43% under its 52-week high of $468.55.

News about Biogen today

  • Sage, biogen now plan to submit depression drug candidate to FDA in second half of 2022. According to today’s article on MarketWatch, "Shares of Sage Therapeutics Inc. gained 0.5% in premarket trading on Wednesday, the day after the company said it and Biogen Inc. plan to submit their experimental depression drug to U.S. regulators for approval in the second half of next year. ", "The good news is that Biogen (OP)/Sage (MP) have confirmation from the FDA that they have the necessary efficacy data to file for major depressive disorder," SVB Leerink’s Marc Goodman told investors on Wednesday. "

The company’s growth estimates for the present quarter and the next is a negative 53.3% and a negative 25.1%, respectively.

Biogen’s Revenue

Year-on-year quarterly revenue growth declined by 24.6%, now sitting on 11.7B for the twelve trailing months.

Volatility

Biogen’s last week, last month’s, and last quarter’s current volatility was a negative 1.71%, a negative 0.47%, and a positive 1.10%, respectively.

Biogen’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.09% (last week), 1.17% (last month), and 1.10% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Biogen’s stock is considered to be overbought (>=80).

Biogen’s Stock Yearly Top and Bottom Value

Biogen’s stock is valued at $268.13 at 08:34 EST, way below its 52-week high of $468.55 and way higher than its 52-week low of $223.25.

Biogen’s Moving Average

Biogen’s worth is way below its 50-day moving average of $298.13 and way under its 200-day moving average of $312.85.

Previous days news about Biogen

  • Biogen says ALS drug did not meet primary endpoint in phase 3 clinical trial. According to MarketWatch on Monday, 18 October, "Shares of Biogen were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS) drug did not meet the primary endpoint in an open-label, Phase 3 clinical trial. ", "These preliminary data may be supportive of some hints of efficacy; however, the study failed the well-understood ALS primary endpoint, and thus we don’t see how Biogen would be able to proceed with a filing with this data," SVB Leerink analyst Marc Goodman told investors on Sunday. "

More news about Biogen.

5. Regeneron Pharmaceuticals (REGN) – Premarket: 2.09%

NASDAQ Composite ended the session with Regeneron Pharmaceuticals jumping 1.59% to $552.11 on Wednesday, after two sequential sessions in a row of losses. NASDAQ Composite rose 0.71% to $15,129.09, after five consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Regeneron Pharmaceuticals’s last close was $543.48, 20.85% below its 52-week high of $686.62.

Regeneron Pharmaceuticals’s Sales

Regeneron Pharmaceuticals’s sales growth is 28.6% for the present quarter and 18.3% for the next. The company’s growth estimates for the current quarter and the next is 7.7% and 8%, respectively.

Regeneron Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 163.2%, now sitting on 12.2B for the twelve trailing months.

Volatility

Regeneron Pharmaceuticals’s last week, last month’s, and last quarter’s current volatility was a negative 0.23%, a negative 1.48%, and a positive 1.34%, respectively.

Regeneron Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.26% (last week), 1.83% (last month), and 1.34% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Regeneron Pharmaceuticals’s stock is considered to be overbought (>=80).

Regeneron Pharmaceuticals’s Stock Yearly Top and Bottom Value

Regeneron Pharmaceuticals’s stock is valued at $552.11 at 08:34 EST, way under its 52-week high of $686.62 and way higher than its 52-week low of $441.00.

Regeneron Pharmaceuticals’s Moving Average

Regeneron Pharmaceuticals’s worth is way below its 50-day moving average of $615.29 and below its 200-day moving average of $563.70.

More news about Regeneron Pharmaceuticals.

6. Pinduoduo (PDD) – Premarket: 2.03%

NASDAQ Composite ended the session with Pinduoduo rising 0.54% to $97.52 on Wednesday while NASDAQ Composite jumped 0.71% to $15,129.09.

Volume

Today’s last reported volume for Pinduoduo is 6592490, 21.5% below its average volume of 8398370.

Pinduoduo’s last close was $97.00, 54.37% below its 52-week high of $212.60.

The company’s growth estimates for the current quarter is a negative 160% and positive 1350% for the next.

Pinduoduo’s Revenue

Year-on-year quarterly revenue growth grew by 89%, now sitting on 85.97B for the twelve trailing months.

Volatility

Pinduoduo’s last week, last month’s, and last quarter’s current volatility was a negative 0.21%, a negative 0.59%, and a positive 3.57%, respectively.

Pinduoduo’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.33% (last week), 3.22% (last month), and 3.57% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pinduoduo’s stock is considered to be oversold (<=20).

Pinduoduo’s Stock Yearly Top and Bottom Value

Pinduoduo’s stock is valued at $97.52 at 08:34 EST, way below its 52-week high of $212.60 and way higher than its 52-week low of $74.12.

Pinduoduo’s Moving Average

Pinduoduo’s value is higher than its 50-day moving average of $96.85 and way under its 200-day moving average of $111.80.

More news about Pinduoduo.

7. United Airlines (UAL) – Premarket: 1.9%

NASDAQ Composite ended the session with United Airlines dropping 2.01% to $46.22 on Wednesday, following the last session’s downward trend. NASDAQ Composite rose 0.71% to $15,129.09, after five successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Volume

Today’s last reported volume for United Airlines is 13879500, 21.25% above its average volume of 11446200.

United Airlines’s last close was $47.17, 25.95% under its 52-week high of $63.70.

United Airlines’s Sales

United Airlines’s sales growth is 237.4% for the current quarter and 162% for the next. The company’s growth estimates for the present quarter and the next is 99.4% and 103.3%, respectively.

United Airlines’s Revenue

Year-on-year quarterly revenue growth grew by 270.9%, now sitting on 14.59B for the twelve trailing months.

Volatility

United Airlines’s last week, last month’s, and last quarter’s current volatility was a negative 0.50%, a positive 0.49%, and a positive 1.81%, respectively.

United Airlines’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.67% (last week), 1.74% (last month), and 1.81% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

United Airlines’s stock is considered to be overbought (>=80).

United Airlines’s Stock Yearly Top and Bottom Value

United Airlines’s stock is valued at $46.22 at 08:34 EST, way under its 52-week high of $63.70 and way above its 52-week low of $32.16.

United Airlines’s Moving Average

United Airlines’s value is below its 50-day moving average of $47.22 and under its 200-day moving average of $51.32.

Previous days news about United Airlines

  • Why United Airlines stock is trading higher during Tuesday's after-hours session. According to Benzinga on Tuesday, 19 October, "Shares of United Airlines Holdings Inc. (NASDAQ: UAL) were trading sharply higher following the release of its third-quarter earnings report. ", "At the time of publication, shares of United Airlines were trading 2.23% higher during after hours at $47.25, reversing losses on the day following the -2.01% pullback during market hours."

More news about United Airlines.

8. Citizens Financial Group (CFG) – Premarket: 1.73%

NYSE Composite ended the session with Citizens Financial Group rising 1.49% to $49.10 on Wednesday while NYSE Composite jumped 0.75% to $16,988.16.

Volume

Today’s last reported volume for Citizens Financial Group is 3466830, 23.17% below its average volume of 4512400.

Citizens Financial Group’s last close was $48.38, 5.4% under its 52-week high of $51.14.

The company’s growth estimates for the current quarter and the next is 66.2% and 13.1%, respectively.

Citizens Financial Group’s Revenue

Year-on-year quarterly revenue growth grew by 41.7%, now sitting on 6.57B for the twelve trailing months.

Volatility

Citizens Financial Group’s last week, last month’s, and last quarter’s current volatility was 0.64%, 1.19%, and 1.57%, respectively.

Citizens Financial Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.64% (last week), 1.82% (last month), and 1.57% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Citizens Financial Group’s stock is considered to be oversold (<=20).

Citizens Financial Group’s Stock Yearly Top and Bottom Value

Citizens Financial Group’s stock is valued at $49.10 at 08:34 EST, below its 52-week high of $51.14 and way above its 52-week low of $25.41.

Citizens Financial Group’s Moving Average

Citizens Financial Group’s value is higher than its 50-day moving average of $45.13 and above its 200-day moving average of $45.68.

More news about Citizens Financial Group.

9. Genmab (GMAB) – Premarket: 1.59%

NASDAQ Composite ended the session with Genmab jumping 1.8% to $45.30 on Wednesday while NASDAQ Composite jumped 0.71% to $15,129.09.

Volume

Today’s last reported volume for Genmab is 187722, 47.08% below its average volume of 354735.

Genmab’s last close was $44.50, 9.31% under its 52-week high of $49.07.

Genmab’s Sales

Genmab’s sales growth is a negative 63.6% for the present quarter and 22.8% for the next. The company’s growth estimates for the ongoing quarter is a negative 86.1% and positive 569.2% for the next.

Genmab’s Revenue

Year-on-year quarterly revenue growth declined by 63.8%, now sitting on 7.32B for the twelve trailing months.

Volatility

Genmab’s last week, last month’s, and last quarter’s current volatility was a positive 0.79%, a negative 0.53%, and a positive 1.43%, respectively.

Genmab’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.79% (last week), 1.88% (last month), and 1.43% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Genmab’s stock is considered to be oversold (<=20).

Genmab’s Stock Yearly Top and Bottom Value

Genmab’s stock is valued at $45.30 at 08:34 EST, under its 52-week high of $49.07 and way above its 52-week low of $30.10.

Genmab’s Moving Average

Genmab’s worth is higher than its 50-day moving average of $44.17 and above its 200-day moving average of $41.87.

More news about Genmab.

10. ResMed (RMD) – Premarket: 1.4%

NYSE Composite ended the session with ResMed jumping 1.23% to $260.16 on Wednesday while NYSE Composite jumped 0.75% to $16,988.16.

Volume

Today’s last reported volume for ResMed is 536572, 8.23% above its average volume of 495735.

ResMed’s last close was $256.99, 14.72% below its 52-week high of $301.34.

The company’s growth estimates for the ongoing quarter and the next is 7.1% and 7.8%, respectively.

ResMed’s Revenue

Year-on-year quarterly revenue growth declined by 0.1%, now sitting on 3.09B for the twelve trailing months.

Volatility

ResMed’s last week, last month’s, and last quarter’s current volatility was a positive 0.62%, a negative 1.11%, and a positive 1.13%, respectively.

ResMed’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.62% (last week), 1.63% (last month), and 1.13% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

ResMed’s stock is considered to be oversold (<=20).

ResMed’s Stock Yearly Top and Bottom Value

ResMed’s stock is valued at $260.16 at 08:34 EST, way below its 52-week high of $301.34 and way above its 52-week low of $174.84.

ResMed’s Moving Average

ResMed’s worth is below its 50-day moving average of $278.78 and above its 200-day moving average of $241.77.

More news about ResMed.

Most Active Premarket Losers Today

1. Novavax (NVAX) – Premarket: -23.82%

NASDAQ Composite ended the session with Novavax falling 3.43% to $160.55 on Wednesday, following the last session’s upward trend. NASDAQ Composite jumped 0.71% to $15,129.09, after five sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Volume

Today’s last reported volume for Novavax is 2962990, 41.8% below its average volume of 5091170.

Novavax’s last close was $166.25, 49.88% below its 52-week high of $331.68.

News about Novavax today

  • Novavax shares plunge to lows since mid-May as Covid-19 vaccine woes continue. According to today’s article on Benzinga, "The method Novavax uses to test the purity of the vaccine has fallen short of the standards of the Food and Drug Administration, Politico reported citing people familiar with the matter. ", "Heterologous Regimen Study Shows More Work Needed For Interpreting Antibody Data: Novavax presented at the World Vaccine Congress Barcelona, the topline immunogenicity and reactogenicity data from a Phase 2 COVID-19 vaccine schedule combinations study conducted by the University of Oxford. "

The company’s growth estimates for the current quarter is a negative 21.8% and positive 213.7% for the next.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 738.6%, now sitting on 1.18B for the twelve trailing months.

Volatility

Novavax’s last week, last month’s, and last quarter’s current volatility was a negative 0.05%, a negative 2.80%, and a positive 5.00%, respectively.

Novavax’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.16% (last week), 5.09% (last month), and 5.00% (last quarter), respectively.

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $160.55 at 08:34 EST, way under its 52-week high of $331.68 and way above its 52-week low of $76.59.

Novavax’s Moving Average

Novavax’s value is way below its 50-day moving average of $214.39 and way under its 200-day moving average of $199.10.

More news about Novavax.

2. Pool Corporation (POOL) – Premarket: -5.28%

NASDAQ Composite ended the session with Pool Corporation jumping 0.88% to $464.51 on Wednesday, after three consecutive sessions in a row of gains. NASDAQ Composite rose 0.71% to $15,129.09, after five consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Volume

Today’s last reported volume for Pool Corporation is 146071, 33.8% below its average volume of 220664.

Pool Corporation’s last close was $460.46, 8.06% below its 52-week high of $500.85.

Pool Corporation’s Sales

Pool Corporation’s sales growth is 37% for the present quarter and 3.6% for the next. The company’s growth estimates for the present quarter and the next is 29.8% and 0.7%, respectively.

Pool Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 4.83B for the twelve trailing months.

Volatility

Pool Corporation’s last week, last month’s, and last quarter’s current volatility was a positive 1.51%, a negative 0.65%, and a positive 1.34%, respectively.

Pool Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.51% (last week), 1.85% (last month), and 1.34% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pool Corporation’s stock is considered to be oversold (<=20).

Pool Corporation’s Stock Yearly Top and Bottom Value

Pool Corporation’s stock is valued at $464.51 at 08:34 EST, below its 52-week high of $500.85 and way higher than its 52-week low of $305.47.

Pool Corporation’s Moving Average

Pool Corporation’s value is higher than its 50-day moving average of $464.24 and above its 200-day moving average of $448.24.

More news about Pool Corporation.

3. Rio Tinto (RIO) – Premarket: -3.89%

NYSE Composite ended the session with Rio Tinto rising 1.01% to $70.89 on Wednesday, after two sequential sessions in a row of losses. NYSE Composite rose 0.75% to $16,988.16, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Rio Tinto is 3041490, 4.63% below its average volume of 3189400.

Rio Tinto’s last close was $70.18, 26.87% below its 52-week high of $95.97.

Rio Tinto’s Revenue

Year-on-year quarterly revenue growth grew by 70.9%, now sitting on 58.33B for the twelve trailing months.

Volatility

Rio Tinto’s last week, last month’s, and last quarter’s current volatility was a positive 0.55%, a negative 0.40%, and a positive 1.88%, respectively.

Rio Tinto’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.42% (last week), 1.68% (last month), and 1.88% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Rio Tinto’s stock is considered to be overbought (>=80).

Rio Tinto’s Stock Yearly Top and Bottom Value

Rio Tinto’s stock is valued at $70.89 at 08:34 EST, way below its 52-week high of $95.97 and way higher than its 52-week low of $55.39.

Rio Tinto’s Moving Average

Rio Tinto’s worth is higher than its 50-day moving average of $70.42 and way below its 200-day moving average of $81.04.

Previous days news about Rio Tinto

  • Rio tinto announces new three-year partnership with telethon. According to Business Insider on Sunday, 17 October, "Rio Tinto specified that this year $4 million donation will be distributed between three health initiatives, The Rio Tinto Diabetes Global Research Centre, Embrace @ Telethon Kids Institute, and The Telethon Trust."

More news about Rio Tinto.

4. Magna International (MGA) – Premarket: -3.69%

NYSE Composite ended the session with Magna International falling 0.55% to $82.96 on Wednesday, following the last session’s downward trend. NYSE Composite rose 0.75% to $16,988.16, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Magna International is 1168940, 8.37% below its average volume of 1275720.

Magna International’s last close was $83.42, 20% under its 52-week high of $104.28.

Magna International’s Sales

Magna International’s sales growth is 4.1% for the present quarter and 0.9% for the next. The company’s growth estimates for the current quarter and the next is a negative 14.4% and a negative 23.7%, respectively.

Magna International’s Revenue

Year-on-year quarterly revenue growth grew by 110.4%, now sitting on 38.91B for the twelve trailing months.

Volatility

Magna International’s last week, last month’s, and last quarter’s current volatility was a negative 0.35%, a positive 0.29%, and a positive 1.58%, respectively.

Magna International’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.81% (last week), 2.00% (last month), and 1.58% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Magna International’s stock is considered to be overbought (>=80).

Magna International’s Stock Yearly Top and Bottom Value

Magna International’s stock is valued at $82.96 at 08:34 EST, way below its 52-week high of $104.28 and way higher than its 52-week low of $49.24.

Magna International’s Moving Average

Magna International’s value is above its 50-day moving average of $78.66 and below its 200-day moving average of $88.25.

More news about Magna International.

5. Interactive Brokers Group (IBKR) – Premarket: -3.65%

NASDAQ Composite ended the session with Interactive Brokers Group jumping 2.95% to $73.73 on Wednesday while NASDAQ Composite rose 0.71% to $15,129.09.

Volume

Today’s last reported volume for Interactive Brokers Group is 855773, 18.27% above its average volume of 723546.

Interactive Brokers Group’s last close was $71.62, 11.11% below its 52-week high of $80.57.

The company’s growth estimates for the present quarter and the next is 35.8% and 2.9%, respectively.

Interactive Brokers Group’s Revenue

Year-on-year quarterly revenue growth grew by 45.9%, now sitting on 2.79B for the twelve trailing months.

Volatility

Interactive Brokers Group’s last week, last month’s, and last quarter’s current volatility was 0.28%, 1.10%, and 1.30%, respectively.

Interactive Brokers Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.45% (last week), 1.91% (last month), and 1.30% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Interactive Brokers Group’s stock is considered to be oversold (<=20).

Interactive Brokers Group’s Stock Yearly Top and Bottom Value

Interactive Brokers Group’s stock is valued at $73.73 at 08:34 EST, under its 52-week high of $80.57 and way higher than its 52-week low of $46.71.

Interactive Brokers Group’s Moving Average

Interactive Brokers Group’s worth is way higher than its 50-day moving average of $65.23 and way higher than its 200-day moving average of $66.32.

More news about Interactive Brokers Group.

6. 10x Genomics (TXG) – Premarket: -3.57%

NASDAQ Composite ended the session with 10x Genomics rising 4.32% to $160.74 on Wednesday while NASDAQ Composite jumped 0.71% to $15,129.09.

Volume

Today’s last reported volume for 10x Genomics is 540648, 11% below its average volume of 607529.

10x Genomics’s last close was $154.09, 26.27% under its 52-week high of $208.99.

10x Genomics’s Sales

10x Genomics’s sales growth is 78.1% for the present quarter and 33.2% for the next. The company’s growth estimates for the current quarter and the next is 70.8% and 97.2%, respectively.

10x Genomics’s Revenue

Year-on-year quarterly revenue growth grew by 170%, now sitting on 405.7M for the twelve trailing months.

Volatility

10x Genomics’s last week, last month’s, and last quarter’s current volatility was a positive 0.04%, a negative 1.39%, and a positive 2.54%, respectively.

10x Genomics’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.76% (last week), 2.87% (last month), and 2.54% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

10x Genomics’s stock is considered to be oversold (<=20).

10x Genomics’s Stock Yearly Top and Bottom Value

10x Genomics’s stock is valued at $160.74 at 08:34 EST, way below its 52-week high of $208.99 and way above its 52-week low of $125.84.

10x Genomics’s Moving Average

10x Genomics’s value is under its 50-day moving average of $162.38 and under its 200-day moving average of $174.64.

More news about 10x Genomics.

7. Credit Suisse Group (CS) – Premarket: -2.45%

NYSE Composite ended the session with Credit Suisse Group jumping 1.39% to $10.60 on Wednesday, following the last session’s downward trend. NYSE Composite jumped 0.75% to $16,988.16, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Volume

Today’s last reported volume for Credit Suisse Group is 1859510, 55.73% below its average volume of 4200950.

Credit Suisse Group’s last close was $10.45, 30.1% under its 52-week high of $14.95.

Credit Suisse Group’s Revenue

Year-on-year quarterly revenue growth declined by 13%, now sitting on 18.19B for the twelve trailing months.

Volatility

Credit Suisse Group’s last week, last month’s, and last quarter’s current volatility was 0.58%, 0.25%, and 1.41%, respectively.

Credit Suisse Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.35% (last week), 1.48% (last month), and 1.41% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Credit Suisse Group’s stock is considered to be overbought (>=80).

Credit Suisse Group’s Stock Yearly Top and Bottom Value

Credit Suisse Group’s stock is valued at $10.60 at 08:34 EST, way below its 52-week high of $14.95 and way above its 52-week low of $9.28.

Credit Suisse Group’s Moving Average

Credit Suisse Group’s value is higher than its 50-day moving average of $10.21 and above its 200-day moving average of $10.41.

More news about Credit Suisse Group.

8. Catalyst Pharmaceuticals (CPRX) – Premarket: -2.24%

NASDAQ Composite ended the session with Catalyst Pharmaceuticals jumping 1.34% to $6.03 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ Composite rose 0.71% to $15,129.09, after five successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 404629, 51.49% below its average volume of 834164.

Catalyst Pharmaceuticals’s last close was $5.95, 9.85% below its 52-week high of $6.60.

Catalyst Pharmaceuticals’s Sales

Catalyst Pharmaceuticals’s sales growth is 18% for the ongoing quarter and 15.6% for the next.

Catalyst Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 126.9M for the twelve trailing months.

Volatility

Catalyst Pharmaceuticals’s last week, last month’s, and last quarter’s current volatility was a negative 1.05%, a positive 1.39%, and a positive 2.18%, respectively.

Catalyst Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.05% (last week), 2.88% (last month), and 2.18% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Catalyst Pharmaceuticals’s stock is considered to be overbought (>=80).

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $6.03 at 08:34 EST, below its 52-week high of $6.60 and way above its 52-week low of $2.88.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s value is way higher than its 50-day moving average of $5.42 and way above its 200-day moving average of $5.38.

More news about Catalyst Pharmaceuticals.

9. Lennar Corporation (LEN) – Premarket: -2.16%

NYSE Composite ended the session with Lennar Corporation falling 0.27% to $99.86 on Wednesday while NYSE Composite rose 0.75% to $16,988.16.

Volume

Today’s last reported volume for Lennar Corporation is 1825910, 8.21% below its average volume of 1989440.

Lennar Corporation’s last close was $100.13, 9.47% below its 52-week high of $110.61.

The company’s growth estimates for the present quarter and the next is 54.7% and 59.6%, respectively.

Lennar Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 21.6%, now sitting on 24.45B for the twelve trailing months.

Volatility

Lennar Corporation’s last week, last month’s, and last quarter’s current volatility was a positive 1.77%, a negative 0.35%, and a positive 1.50%, respectively.

Lennar Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.60% (last week), 1.75% (last month), and 1.50% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Lennar Corporation’s stock is considered to be oversold (<=20).

Lennar Corporation’s Stock Yearly Top and Bottom Value

Lennar Corporation’s stock is valued at $99.86 at 08:34 EST, below its 52-week high of $110.61 and way higher than its 52-week low of $69.41.

Lennar Corporation’s Moving Average

Lennar Corporation’s value is higher than its 50-day moving average of $99.68 and below its 200-day moving average of $100.57.

More news about Lennar Corporation.

10. Deutsche Bank (DB) – Premarket: -2.1%

NYSE Composite ended the session with Deutsche Bank jumping 0.53% to $13.36 on Wednesday while NYSE Composite rose 0.75% to $16,988.16.

Volume

Today’s last reported volume for Deutsche Bank is 4472310, 32.28% above its average volume of 3380850.

Deutsche Bank’s last close was $13.29, 13.36% below its 52-week high of $15.34.

The company’s growth estimates for the current quarter is 200% and a drop 76.2% for the next.

Deutsche Bank’s Revenue

Year-on-year quarterly revenue growth grew by 22.6%, now sitting on 23.56B for the twelve trailing months.

Volatility

Deutsche Bank’s last week, last month’s, and last quarter’s current volatility was 1.51%, 0.61%, and 1.57%, respectively.

Deutsche Bank’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.51% (last week), 1.64% (last month), and 1.57% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Deutsche Bank’s stock is considered to be oversold (<=20).

Deutsche Bank’s Stock Yearly Top and Bottom Value

Deutsche Bank’s stock is valued at $13.36 at 08:34 EST, way below its 52-week high of $15.34 and way above its 52-week low of $8.83.

Deutsche Bank’s Moving Average

Deutsche Bank’s worth is above its 50-day moving average of $12.68 and above its 200-day moving average of $13.02.

More news about Deutsche Bank.

Stay up to date with our premarket winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here